Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) is anticipated to issue its results before the market opens on Thursday, November 12th. Analysts expect Zealand Pharma A/S to announce earnings of ($1.5714) per share and revenue of $8.40 million for the quarter.
Zealand Pharma A/S Price Performance
Shares of OTCMKTS ZLDPF opened at $34.63 on Thursday. The business has a fifty day moving average price of $40.13 and a two-hundred day moving average price of $47.55. The stock has a market capitalization of $2.48 billion, a PE ratio of 5.74 and a beta of 0.99. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.98 and a quick ratio of 13.98. Zealand Pharma A/S has a fifty-two week low of $33.08 and a fifty-two week high of $83.12.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on ZLDPF. Barclays cut Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 8th. Jefferies Financial Group cut shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. Finally, Zacks Research upgraded shares of Zealand Pharma A/S from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 12th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Hold”.
Get Our Latest Stock Analysis on Zealand Pharma A/S
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a Denmark-based biotechnology company focused on discovering, developing and commercializing peptide-based medicines. Its research is primarily directed toward metabolic and gastrointestinal diseases, including obesity, diabetes and rare disorders. The company develops therapies designed to address significant unmet medical needs, often using innovative peptide structures and delivery approaches.
Zealand’s portfolio has included dasiglucagon, a glucagon analogue developed for the treatment of severe hypoglycemia.
Featured Stories
- Five stocks we like better than Zealand Pharma A/S
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
